Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 1
1998 2
2000 3
2001 5
2002 3
2003 4
2006 1
2007 2
2008 2
2009 4
2010 4
2011 3
2012 2
2013 8
2014 4
2015 8
2016 5
2017 3
2018 2
2019 6
2020 6
2021 16
2022 13
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Among authors: hocqueloux l. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
Hubert M, Guivel-Benhassine F, Bruel T, Porrot F, Planas D, Vanhomwegen J, Wiedemann A, Burrel S, Marot S, Palich R, Monsel G, Diombera H, Gallien S, Lopez-Zaragoza JL, Vindrios W, Taieb F, Fernandes-Pellerin S, Delhaye M, Laude H, Arowas L, Ungeheuer MN, Hocqueloux L, Pourcher V, Prazuck T, Marcelin AG, Lelièvre JD, Batéjat C, Lévy Y, Manuguerra JC, Schwartz O. Hubert M, et al. Among authors: hocqueloux l. Cell Host Microbe. 2023 Jun 14;31(6):937-948.e4. doi: 10.1016/j.chom.2023.05.001. Epub 2023 May 5. Cell Host Microbe. 2023. PMID: 37196656 Free PMC article.
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Hocqueloux L, Lefeuvre S, Bois J, Brucato S, Alix A, Valentin C, Peyro-Saint-Paul L, Got L, Fournel F, Dargere S, Prazuck T, Fournier A, Gregoire N, McNicholl I, Parienti JJ. Hocqueloux L, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):161-168. doi: 10.1093/jac/dkac369. J Antimicrob Chemother. 2022. PMID: 36322475 Free PMC article. Clinical Trial.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Boland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S; COVID-SER study group; Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Among authors: hocqueloux l. bioRxiv [Preprint]. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873. bioRxiv. 2024. PMID: 38045308 Free PMC article. Updated. Preprint.
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.
Molinos-Albert LM, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J, Schwartz O, Rouzioux C, Meyer L, Hocqueloux L, Sáez-Cirión A, Mouquet H; ANRS VISCONTI Study Group. Molinos-Albert LM, et al. Among authors: hocqueloux l. Nat Commun. 2022 Apr 11;13(1):1944. doi: 10.1038/s41467-022-29511-1. Nat Commun. 2022. PMID: 35410989 Free PMC article.
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O. Planas D, et al. Among authors: hocqueloux l. Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23. Nature. 2022. PMID: 35016199
Posttreatment controllers: what do they tell us?
Rouzioux C, Hocqueloux L, Sáez-Cirión A. Rouzioux C, et al. Among authors: hocqueloux l. Curr Opin HIV AIDS. 2015 Jan;10(1):29-34. doi: 10.1097/COH.0000000000000123. Curr Opin HIV AIDS. 2015. PMID: 25402707 Free article. Review.
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
Molinos-Albert LM, Baquero E, Bouvin-Pley M, Lorin V, Charre C, Planchais C, Dimitrov JD, Monceaux V, Vos M; ANRS VISCONTI Study Group; Hocqueloux L, Berger JL, Seaman MS, Braibant M, Avettand-Fenoël V, Sáez-Cirión A, Mouquet H. Molinos-Albert LM, et al. Among authors: hocqueloux l. Cell Host Microbe. 2023 Aug 9;31(8):1275-1287.e8. doi: 10.1016/j.chom.2023.06.006. Epub 2023 Jul 10. Cell Host Microbe. 2023. PMID: 37433296
113 results